论文部分内容阅读
目的:探讨钙结合蛋白S100A4与卵巢癌细胞顺铂耐药的关系。方法:MTT法测定顺铂对卵巢癌顺铂敏感细胞株A2780和耐药株CP70的半效抑制浓度(IC50);分别应用免疫细胞化学、Western blot和实时荧光定量PCR检测A2780和CP70细胞株中S100A4的差异表达,观察顺铂处理CP70细胞后S100A4在蛋白水平及基因水平的动态变化。结果:顺铂对A2780和CP70的IC50分别为20.88μmol/ml和57.10μmol/ml。S100A4蛋白在二者中均以胞浆表达为主;CP70中S100A4 mRNA水平和蛋白水平的表达均显著高于A2780;经顺铂处理CP70后,S100A4的表达呈剂量-时间依赖性。结论:S100A4的高表达与卵巢癌顺铂化疗耐药有关。
Objective: To investigate the relationship between calcium-binding protein S100A4 and cisplatin-resistant ovarian cancer cells. Methods: The half-inhibitory concentration (IC50) of cisplatin on the cisplatin-sensitive ovarian cancer cell line A2780 and the resistant strain CP70 were determined by MTT assay. Immunocytochemistry, Western blot and real-time fluorescent quantitative PCR were used to detect the inhibitory concentrations S100A4 expression differences, to observe the cisplatin CP70 cells treated with S100A4 at the protein level and gene level dynamic changes. Results: The IC50 of cisplatin to A2780 and CP70 were 20.88μmol / ml and 57.10μmol / ml, respectively. The expression of S100A4 protein in both cytoplasm and cytoplasm was predominant. The expression of S100A4 mRNA and protein in CP70 was significantly higher than that in A2780. After cisplatin treatment, the expression of S100A4 was dose-dependent. Conclusion: The overexpression of S100A4 is associated with chemoresistance to cisplatin in ovarian cancer.